Posted by Michael Wonder on 02 Mar 2021
ICER publishes Final Evidence Report and policy recommendations on new therapies for high cholesterol
2 March 2021 - For bempedoic acid, independent appraisal committee votes that the evidence is not adequate to demonstrate a net health benefit over usual care for the entire population of eligible patients, but is adequate when focusing on patients unable to take statins and patients with heterozygous familial hypercholesterolemia; at current pricing the committee judged the long-term value for money as low to intermediate, with a 36% discount needed to reach ICER’s health-benefit price benchmark for the entire patient population.
The Institute for Clinical and Economic Review today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of inclisiran (Novartis), bempedoic acid (Nexletol, Esperion Therapeutics), and bempedoic acid/ezetimibe (Nexlizet, Esperion Therapeutics) for treating heterozygous familial hypercholesterolaemia and for secondary prevention of atherosclerotic cardiovascular disease.
